PROTECTIVE EFFECT OF DIOSGENIN AGAINST CARBON TETRACHLORIDE AND CISPLATIN INDUCED HEPATOTOXICITY IN RATS
Abstract viewed = 154 times,
PDF downloaded = 83 times.
Article Sidebar
Published
Jul 31, 2018
Section
Original Research Articles
Main Article Content
Abstract
Background: Activation of hepatic stellate cells (HSC) plays central role in the development of liver fibrosis. In HSC activation, the transforming growth factor-β1 (TGF-β1) is considered to be the main stimuli factor. Diosgenin are the steroidal saponin and found in Trigonella foenum graecum Linn (Fenugreek) and some other species of Dioscorea. Diosgenin attenuates HSC activation by inhibiting transforming growth factor-β. Aim: In present study an attempt was made to explore the effect of diosgenin on liver fibrosis. Methods: Liver fibrosis was induced in rats by carbon tetrachloride (CCl4) 1 ml/kg intraperitoneally twice a week for 28 days and cisplatin 3mg/kg intraperitoneally at 0, 1, 3 week for 4 weeks. The extent of liver fibrosis was assessed by measuring the weight of liver and levels of total bilirubin (TBL), hydroxyproline (HP) and serum enzymes due to deposition of extracellular matrix (ECM). Results: The administration of diosgenin reduced the liver weight of CCl4 and cisplatin treated animals and reduced the TBL, HP level and serum enzymes significantly and inhibited liver fibrosis induced by CCl4 and cisplatin. Conclusion: The result obtained in the present investigation, Diosgenin treatment exerted significant hepatoprotective effect in animals by inhibiting ECM deposition and HSCs activation.Â
Article Details
How to Cite
Nimbalkar, V. V., Shelke, R. P., Kadu, U. E., & Gaikwad, P. M. (2018). PROTECTIVE EFFECT OF DIOSGENIN AGAINST CARBON TETRACHLORIDE AND CISPLATIN INDUCED HEPATOTOXICITY IN RATS. International Journal of Clinical and Biomedical Research, 4(3), 50-56. https://doi.org/10.31878/ijcbr.2018.43.11
Copyright (c) 2018 Vikram V Nimbalkar, Ravina P Shelke, Urmila E Kadu, Pandurang M Gaikwad
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allow the author(s) to hold the copyright without restrictions.
- The journal allow the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.
References
1. Thaakur SR, Saraswathy GR, Maheswari E, Kumar NS, Hazarathiah T, Sowmya K, et al. Inhibition of CCl4- induced liver fibrosis by Trigonella foenum-graecum Linn. Natural Product Radiance. 2007;6 (1):11-17.
2. Xie WL, Jiang R, Shen XL, Chen ZY, Deng XM. Diosgenin attenuates hepatic stellate cell activation through transforming growth factor-β/Smad signaling pathway. Int J Clin Exp Med. 2015;8(11):20323-20329.
3. Elpek GO. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol. 2014;20(23):7260-7276.
4. Henderson NC, Iredale JP. Liver ï¬brosis: cellular mechanisms of progression and resolution. Clinical Science. 2007:112:265–280.
5. Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis-associated steatosis. World J Gastroenterol. 2015;21(46):12989-12995.
6. Bert F. Liver Fibrosis: Difficulties in Diagnostic and Treatment: A Review. Gastro Med Res. 2017;1(1):1-8.
7. Weiskirchen R, Tacke F. Liver Fibrosis: Which Mechanisms Matter? Clinical Liver Disease. 2016;8(4):94-99.
8. Lingwal P, Bhatt GK, Kothiyal P. Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis. International Journal of Pharma Research & Review. 2015;4(7):32-37.
9. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol. 2006;12(46):7413-7420.
10. Chen SR, Chen XP, Lu JJ, Wang Y, Wang YT. Potent natural products and herbal medicines for treating liver fibrosis. Chinese Medicine.2015;10(7):1-13.
11. Yuan Q, Wu X, Huang W, Gong G, et al. Acute toxicity and sub-chronic toxicity of steroidal saponins from Dioscorea zingiberensis C.H. Wright in rodents. Journal of Ethnopharmacology. 2009;126(3):543–550.
12. Dong S, Chen QL, Song YN, Sun Y, Wei B, Li XY, et al. mechanism of CCl4-induced liver fibrosis with combined transcriptomic and proteomic analysis. Journal of Toxicological Sciences. 2016;41(4);561-572.
13. Mir M, Arab MR, Shahraki MR. Toxic effects of cisplatin on hepatocytes and liver enzymes of rats. Anatomical Science. 2015;12(4):171-176.
14. Katagiri D, Hamasaki Y, Doi K, Negishi K, et al. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. Kidney International. 2016;89:374-385.
15. Rajesh MG, Latha MS. Protective activity of Glycyrrhiza glabra Linn. On carbon tetrachloride induced peroxidative damage. Indian J Pharmacol. 2004;36(5):284-287.
16. Mustafa I, Elif O, Mukaddes G, Seda T. Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin-induced oxidative damage to liver in rat. Cell Biochem Funct. 2006;24:357–361.
2. Xie WL, Jiang R, Shen XL, Chen ZY, Deng XM. Diosgenin attenuates hepatic stellate cell activation through transforming growth factor-β/Smad signaling pathway. Int J Clin Exp Med. 2015;8(11):20323-20329.
3. Elpek GO. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol. 2014;20(23):7260-7276.
4. Henderson NC, Iredale JP. Liver ï¬brosis: cellular mechanisms of progression and resolution. Clinical Science. 2007:112:265–280.
5. Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis-associated steatosis. World J Gastroenterol. 2015;21(46):12989-12995.
6. Bert F. Liver Fibrosis: Difficulties in Diagnostic and Treatment: A Review. Gastro Med Res. 2017;1(1):1-8.
7. Weiskirchen R, Tacke F. Liver Fibrosis: Which Mechanisms Matter? Clinical Liver Disease. 2016;8(4):94-99.
8. Lingwal P, Bhatt GK, Kothiyal P. Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis. International Journal of Pharma Research & Review. 2015;4(7):32-37.
9. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol. 2006;12(46):7413-7420.
10. Chen SR, Chen XP, Lu JJ, Wang Y, Wang YT. Potent natural products and herbal medicines for treating liver fibrosis. Chinese Medicine.2015;10(7):1-13.
11. Yuan Q, Wu X, Huang W, Gong G, et al. Acute toxicity and sub-chronic toxicity of steroidal saponins from Dioscorea zingiberensis C.H. Wright in rodents. Journal of Ethnopharmacology. 2009;126(3):543–550.
12. Dong S, Chen QL, Song YN, Sun Y, Wei B, Li XY, et al. mechanism of CCl4-induced liver fibrosis with combined transcriptomic and proteomic analysis. Journal of Toxicological Sciences. 2016;41(4);561-572.
13. Mir M, Arab MR, Shahraki MR. Toxic effects of cisplatin on hepatocytes and liver enzymes of rats. Anatomical Science. 2015;12(4):171-176.
14. Katagiri D, Hamasaki Y, Doi K, Negishi K, et al. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. Kidney International. 2016;89:374-385.
15. Rajesh MG, Latha MS. Protective activity of Glycyrrhiza glabra Linn. On carbon tetrachloride induced peroxidative damage. Indian J Pharmacol. 2004;36(5):284-287.
16. Mustafa I, Elif O, Mukaddes G, Seda T. Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin-induced oxidative damage to liver in rat. Cell Biochem Funct. 2006;24:357–361.